Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (7): 651-654.DOI: 10.3969/j.issn.1673-8640.2020.07.005
Previous Articles Next Articles
LI Yong, SHI Yuanyuan, ZHU Guoqing, YANG Jiayu, XIA Yonghui, RU Yongxin, YANG Donglin
Received:2019-05-18
Online:2020-07-30
Published:2020-08-04
CLC Number:
LI Yong, SHI Yuanyuan, ZHU Guoqing, YANG Jiayu, XIA Yonghui, RU Yongxin, YANG Donglin. Prediction of platelet implantation by immature platelet ratio in allogeneic stem cell transplantation[J]. Laboratory Medicine, 2020, 35(7): 651-654.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.07.005
| 样本 | XE-2100 | XN-9000 | ||
|---|---|---|---|---|
| PLT计数/ (×109/L) | CV/% | PLT计数/ (×109/L) | CV/% | |
| 质控品 | ||||
| 1 | 63.6±2.6 | 4.09 | 93.5±1.9 | 2.03 |
| 2 | 232±5.8 | 2.50 | 257.8±4.6 | 1.78 |
| 3 | 539±5.5 | 1.00 | 571.2±5 | 0.88 |
| AA | ||||
| 1 | 5.6±1.1 | 19.6 | 4.2±0.5 | 11.90 |
| 2 | 9.3±1.8 | 19.4 | 8.1±0.8 | 9.90 |
| ITP | ||||
| 1 | 37.1±1.7 | 4.60 | 37.6±0.6 | 1.60 |
| 2 | 21.8±1.2 | 5.50 | 22.6±0.9 | 4.00 |
| 样本 | XE-2100 | XN-9000 | ||
|---|---|---|---|---|
| PLT计数/ (×109/L) | CV/% | PLT计数/ (×109/L) | CV/% | |
| 质控品 | ||||
| 1 | 63.6±2.6 | 4.09 | 93.5±1.9 | 2.03 |
| 2 | 232±5.8 | 2.50 | 257.8±4.6 | 1.78 |
| 3 | 539±5.5 | 1.00 | 571.2±5 | 0.88 |
| AA | ||||
| 1 | 5.6±1.1 | 19.6 | 4.2±0.5 | 11.90 |
| 2 | 9.3±1.8 | 19.4 | 8.1±0.8 | 9.90 |
| ITP | ||||
| 1 | 37.1±1.7 | 4.60 | 37.6±0.6 | 1.60 |
| 2 | 21.8±1.2 | 5.50 | 22.6±0.9 | 4.00 |
| 样本编号 | 中性粒细胞绝对数≥ 0.5×109/L | IPF> 3.0% | A-IPF >0.2×109/L | PLT计数≥ 20×109/L | 提前预测天数 | |
|---|---|---|---|---|---|---|
| IPF | A-IPF | |||||
| 1 | 16 | 15 | 14 | 16 | 1 | 2 |
| 2 | 13 | 12 | 11 | 12 | 0 | 1 |
| 3 | 11 | 10 | 9 | 12 | 2 | 3 |
| 4 | 11 | 9 | 9 | 12 | 3 | 3 |
| 5 | 12 | 11 | 8 | 12 | 1 | 4 |
| 6 | 19 | 19 | 19 | 20 | 1 | 1 |
| 7 | 11 | 9 | 7 | 12 | 3 | 5 |
| 8 | 16 | 16 | 15 | 18 | 2 | 3 |
| 9 | 14 | 16 | 11 | 12 | –4 | 1 |
| 10 | 32 | 31 | 31 | 32 | 1 | 1 |
| 11 | 16 | 12 | 11 | 13 | 1 | 2 |
| 12 | 12 | 13 | 11 | 12 | –1 | 1 |
| 13 | 22 | 20 | 20 | 22 | 2 | 2 |
| 14 | 14 | 14 | 12 | 15 | 1 | 3 |
| 15 | 18 | 14 | 12 | 17 | 3 | 5 |
| 16 | 27 | 39 | 38 | 39 | 0 | 1 |
| 17 | 11 | 12 | 11 | 15 | 3 | 4 |
| 18 | 18 | 21 | 20 | 20 | –1 | 0 |
| 19 | 13 | 12 | 9 | 15 | 3 | 6 |
| 20 | 14 | 13 | 13 | 13 | 0 | 0 |
| 21 | 15 | 13 | 12 | 14 | 1 | 2 |
| 22 | 15 | 18 | 17 | 20 | 2 | 3 |
| 23 | 11 | 12 | 11 | 14 | 2 | 3 |
| 24 | 12 | 12 | 10 | 14 | 2 | 4 |
| 25 | 15 | 15 | 15 | 17 | 2 | 2 |
| 26 | 14 | 14 | 13 | 15 | 1 | 2 |
| 27 | 11 | 11 | 10 | 11 | 0 | 1 |
| 28 | 15 | 16 | 16 | 18 | 2 | 2 |
| 29 | 11 | 12 | 11 | 13 | 1 | 2 |
| 30 | 18 | 18 | 17 | 21 | 3 | 4 |
| 样本编号 | 中性粒细胞绝对数≥ 0.5×109/L | IPF> 3.0% | A-IPF >0.2×109/L | PLT计数≥ 20×109/L | 提前预测天数 | |
|---|---|---|---|---|---|---|
| IPF | A-IPF | |||||
| 1 | 16 | 15 | 14 | 16 | 1 | 2 |
| 2 | 13 | 12 | 11 | 12 | 0 | 1 |
| 3 | 11 | 10 | 9 | 12 | 2 | 3 |
| 4 | 11 | 9 | 9 | 12 | 3 | 3 |
| 5 | 12 | 11 | 8 | 12 | 1 | 4 |
| 6 | 19 | 19 | 19 | 20 | 1 | 1 |
| 7 | 11 | 9 | 7 | 12 | 3 | 5 |
| 8 | 16 | 16 | 15 | 18 | 2 | 3 |
| 9 | 14 | 16 | 11 | 12 | –4 | 1 |
| 10 | 32 | 31 | 31 | 32 | 1 | 1 |
| 11 | 16 | 12 | 11 | 13 | 1 | 2 |
| 12 | 12 | 13 | 11 | 12 | –1 | 1 |
| 13 | 22 | 20 | 20 | 22 | 2 | 2 |
| 14 | 14 | 14 | 12 | 15 | 1 | 3 |
| 15 | 18 | 14 | 12 | 17 | 3 | 5 |
| 16 | 27 | 39 | 38 | 39 | 0 | 1 |
| 17 | 11 | 12 | 11 | 15 | 3 | 4 |
| 18 | 18 | 21 | 20 | 20 | –1 | 0 |
| 19 | 13 | 12 | 9 | 15 | 3 | 6 |
| 20 | 14 | 13 | 13 | 13 | 0 | 0 |
| 21 | 15 | 13 | 12 | 14 | 1 | 2 |
| 22 | 15 | 18 | 17 | 20 | 2 | 3 |
| 23 | 11 | 12 | 11 | 14 | 2 | 3 |
| 24 | 12 | 12 | 10 | 14 | 2 | 4 |
| 25 | 15 | 15 | 15 | 17 | 2 | 2 |
| 26 | 14 | 14 | 13 | 15 | 1 | 2 |
| 27 | 11 | 11 | 10 | 11 | 0 | 1 |
| 28 | 15 | 16 | 16 | 18 | 2 | 2 |
| 29 | 11 | 12 | 11 | 13 | 1 | 2 |
| 30 | 18 | 18 | 17 | 21 | 3 | 4 |
| [1] | GREER J P,ARBER D A,GLADER B,et al.Wintrobe's clinical hematology[M]. 13th ed. Philadelphia:Lippincott Williams & Wilkins,2013. |
| [2] | 胡文静,叶盛,费荣,等. 血液病患者预防性血小板输注的研究进展[J]. 临床血液学杂志,2016,29(1):86-88. |
| [3] | KAUFMAN R M,DJULBEGOVIC B,GERNSHEIMER T,et al.Platelet transfusion:a clinical practice guideline from the AABB[J]. Ann Intern Med,2015,162(3):205-213. |
| [4] | BRIGGS C,HART D,KUNKA S,et al.Immature platelet fraction measurement:a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation[J]. Transfus Med,2006,16(2):101-109. |
| [5] | MICHUR H,MALANKA K,SZCZEPISKI A,et al.Reticulated platelets as a marker of platelet recovery after allogeneic stem cell transplantation[J]. Int J Lab Hematol,2008,30(6):519-525. |
| [6] | TAKAMI A,SHIBAYAMA M,ORITO M,et al.Immature platelet fraction for prediction of platelet engraftment after allogeneic stem cell transplantation[J]. Bone Marrow Transplant,2007,39(8):501-507. |
| [7] | MARTINELLI G,MERLO P,FANTASIA R,et al.Reticulated platelet monitoring after autologous peripheral haematopoietic progenitor cell transplantation[J]. Transfus Apher Sci,2009,40(3):175-181. |
| [8] | YAMAOKA G,KUBOTA Y,NOMURA T,et al.The immature platelet fraction is a useful marker for predicting the timing of platelet recovery in patients with cancer after chemotherapy and hematopoietic stem cell transplantation[J]. Int J Lab Hematol,2010,32(6 Pt 1):e208-e216. |
| [9] | GONÇALO A P,BARBOSA I L,CAMPILHO F,et al.Predictive value of immature reticulocyte and platelet fractions in hematopoietic recovery of allograft patients[J]. Transplant Proc,2011,43(1):241-243. |
| [10] | KIENAST J,SCHMITZ G.Flow cytometric analysis of thiazole orange uptake by platelets:a diagnostic aid in the evaluation of thrombocytopenic disorders[J]. Blood,1990,75(1):116-121. |
| [11] | RICHARDS E M,BAGLIN T P.Quantitation of reticulated platelets:methodology and clinical application[J]. Br J Haematol,1995,91(2):445-451. |
| [12] | BARSAM S J,PSAILA B,FORESTIER M,et al.Platelet production and platelet destruction:assessing mechanisms of treatment effect in immune thrombocytopenia[J]. Blood,2011,117(21):5723-5732. |
| [13] | KURATA Y,HAYASHI S,KIYOI T,et al.Diagnostic value of tests for reticulated platelets,plasma glycocalicin,and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia[J]. Am J Clin Pathol,2001,115(5):656-664. |
| [14] | KUWANA M,KURATA Y,FUJIMURA K,et al.Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura:evaluation by multi-center prospective study[J]. J Thromb Haemost,2006,4(9):1936-1943. |
| [15] | 林孝怡,陈骊婷,沈韻. Sysmex XN血液分析仪未成熟血小板比率在血小板减少性疾病中的应用[J]. 检验医学,2019,34(2):159-161. |
| [16] | SAKURAGI M,HAYASHI S,MARUYAMA M,et al. Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disorders[J]. Int J Hematol,2015,101(4):369-375. |
| [17] | 夏永辉,李筱梅,李勇,等. IPF相关参数参考范围调查及其在血小板减少性疾病诊断中的探讨[J]. 检验医学,2012,27(9):745-748. |
| [18] | SAKURAGI M,HAYASHI S,MARUYAMA M,et al.Immature platelet fraction (IPF) as a predictive value for thrombopoietic recovery after allogeneic stem cell transplantation[J]. Int J Hematol,2018,107(3):320-326. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||